Application of pathways for inhibiting induction of IFN-I (interferon-I) to ARG1 (arginase 1) to preparing antitumor pharmaceutical compositions

The invention provides application of pathways for inhibiting induction of IFN-I (interferon-I) to ARG1 (arginase 1) in tumor-associated mononuclear/macrophages to preparing IFN-I anti-solid-tumor pharmaceutical compositions. A critical step includes catalyzing arginine catabolism by ARG1 (arginase 1) proteins, and tumor promotion effects can be realized by expression of the ARG1 proteins in tumormicro-environments. As revealed by related research, expression of the ARG1 can be accidentally intensely inhibited by IFN-I signals in the tumor-associated mononuclear/macrophages in IFN-I anti-solid-tumor therapy models, and accordingly IFN-I anti-solid-tumor therapy effects can be affected by the pathways for inhibiting the induction of the IFN-I to the ARG1. The application has the advantagesthat negative effects can be eliminated by the pathways for inhibiting the induction of the IFN-I to the ARG1, anti-solid-tumor curative effects of the IFN-I can be greatly enhanced, and antitumor synergistic effects can be r